- Conditions
- Idiopathic Juxtafoveal Telangiectasia
- Interventions
- NT-501 implant
- Biological
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 98
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mastocytosis
- Interventions
- Not listed
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Timolol Gel, Placebo Gel
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epistaxis
- Interventions
- Doxycycline, Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Port-Wine Stain, Rosacea, Telangiectasia, Angioma
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501, Sham Procedure
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Macular Telangiectasia
- Interventions
- 577-nm PASCAL laser
- Device
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Other
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Breast Cancer, Radiation-Induced Telangiectasias
- Interventions
- questionnaires
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Perifoveal Telangiectasia
- Interventions
- anecortave acetate
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Interventions
- liposomal bupivacaine
- Drug
- Lead sponsor
- Jose Soberon, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Leg Veins
- Interventions
- Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine, Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
- Drug
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Submucosal Bevacizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501 CNTF Implant
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
- Conditions
- Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
- Drug
- Lead sponsor
- Lejla Vajzovic, MD, FASRS
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Temozolomide, Tuvusertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Irvine, California • La Jolla, California • Orange, California + 17 more
- Conditions
- Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia, Hematochezia, Melena
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Northport Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Worcester, Massachusetts • Northport, New York
- Conditions
- Metastatic Cancer
- Interventions
- Palliative radiotherapy
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
- Interventions
- 532 nm KTP laser
- Device
- Lead sponsor
- Cutera Inc.
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Edina, Minnesota
- Conditions
- Ataxia-Telangiectasia (A-T)
- Interventions
- A-T iPS cell line, Carrier patients iPS cell line
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 3 Years to 100 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501, Sham
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Colorado Springs, Colorado • Atlanta, Georgia + 18 more
- Conditions
- Telangiectasia, Spider Veins
- Interventions
- Ultherapy
- Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- Serine, Fenofibrate
- Dietary Supplement · Drug
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more
- Conditions
- Epistaxis, Hereditary Hemorrhagic Telangiectasia
- Interventions
- Sclerotherapy, Standard Treatment
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota